Clinical presentation and treatment of gastrointestinal stromal tumors
| Autor: | Nello Grassi, Gianni Pantuso, Salvatore Vieni, Salvatore Fricano, Maria Rosaria Valerio, Luigi Sandonato, Mario Adelfio Latteri, Fabio Fulfaro, Nicola Gebbia, Calogero Cipolla, Rea Lo Dico |
|---|---|
| Přispěvatelé: | CIPOLLA C, FULFARO F, SANDONATO L, FRICANO S, PANTUSO G, GRASSI N, VIENI, S, VALERIO MR, LO DICO R, GEBBIA N, LATTERI M |
| Jazyk: | angličtina |
| Rok vydání: | 2006 |
| Předmět: |
Male
Reoperation Cancer Research medicine.medical_specialty Gastrointestinal Stromal Tumors Antineoplastic Agents Disease Gastroenterology Piperazines 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Adjuvant therapy Humans Radical surgery Protein Kinase Inhibitors Aged Gastrointestinal tract business.industry Standard treatment Imatinib General Medicine Middle Aged Survival Analysis Surgery Pyrimidines Treatment Outcome Imatinib mesylate gastrointestinal stromal tumors treatment Oncology Chemotherapy Adjuvant 030220 oncology & carcinogenesis Localized disease Benzamides Imatinib Mesylate Female 030211 gastroenterology & hepatology business medicine.drug |
| Popis: | Aims and background Gastrointestinal stromal tumors (GISTs), although rare, are the most common mesenchymal neoplasms affecting the gastrointestinal tract. We present our experience in the treatment of localized and metastatic disease and a review of literature. Patients and methods Nine patients were observed from April 2002 to July 2004. Eight tumors were in the gastric area and J was in the small bowel. In 5 cases, complete surgical removal was performed, and none of these patients underwent adjuvant therapy. The remaining 4 cases, with locally advanced or recurrent disease, were treated with imatinib. Results The patients with localized disease treated only by surgery did not relapse. In the patients with locally advanced or metastatic disease treated by imatinib, we observed 3 partial responses, and one case was not assessable because he had no measurable disease. In 2 of 3 responders, it was possible to perform a new radical surgery. Conclusions Our series is too small to draw any conclusion. According to our review of the literature, surgery remains the standard treatment for non-metastatic GISTs. Imatinib mesylate represents a major breakthrough in the treatment of advanced GISTs and is the first effective systemic therapy for the disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|